Christopher W. Schmidt

List of Publications by Year
in descending order

61	4,066	109321	123424
papers	citations	35 h-index	61 g-index

62	62	62	6313
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 2020, 11, 2408.	12.8	86
2	Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget, 2016, 7, 4624-4631.	1.8	235
3	Exome Sequencing to Predict Neoantigens in Melanoma. Cancer Immunology Research, 2015, 3, 992-998.	3.4	50
4	Generation of CD8⁺T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy. Cancer Biology and Therapy, 2015, 16, 1323-1331.	3.4	20
5	Exploration of peptides bound to <scp>MHC</scp> class I molecules in melanoma. Pigment Cell and Melanoma Research, 2015, 28, 281-294.	3.3	31
6	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget, 2015, 6, 17753-17763.	1.8	81
7	High Efficiency Ex Vivo Cloning of Antigen-Specific Human Effector T Cells. PLoS ONE, 2014, 9, e110741.	2.5	4
8	Melanomas of unknown primary have a mutation profile consistent with cutaneous sunâ€exposed melanoma. Pigment Cell and Melanoma Research, 2013, 26, 852-860.	3.3	48
9	In Vitro Analysis of Breast Cancer Cell Line Tumourspheres and Primary Human Breast Epithelia Mammospheres Demonstrates Inter- and Intrasphere Heterogeneity. PLoS ONE, 2013, 8, e64388.	2.5	55
10	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nature Genetics, 2012, 44, 165-169.	21.4	170
11	A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 2012, 11, 888-897.	4.1	45
12	Identification of TFG (TRKâ€fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes Chromosomes and Cancer, 2012, 51, 452-461.	2.8	25
13	Melanoma vaccines: developments over the past 10 years. Expert Review of Vaccines, 2011, 10, 853-873.	4.4	27
14	A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 2011, 480, 99-103.	27.8	413
15	Cross-Platform Array Screening Identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as Genes Frequently Silenced by Methylation in Melanoma. PLoS ONE, 2011, 6, e26121.	2.5	73
16	Fulminant Infectious Mononucleosis and Recurrent Epsteinâ€Barr Virus Reactivation in an Adolescent. Clinical Infectious Diseases, 2010, 50, e34-e37.	5.8	4
17	A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice. Cancer Research, 2010, 70, 7476-7488.	0.9	149
18	Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS ONE, 2010, 5, e9685.	2.5	181

#	Article	IF	Citations
19	Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. British Journal of Cancer, 2009, 100, 322-333.	6.4	90
20	Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine, 2009, 27, 3053-3062.	3.8	35
21	Antigens for cancer immunotherapy. Seminars in Immunology, 2008, 20, 286-295.	5.6	147
22	Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Research, 2008, 10, 210.	5.0	109
23	Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. Journal of Clinical Neuroscience, 2008, 15, 114-121.	1.5	74
24	Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. British Journal of Cancer, 2007, 97, 1251-1259.	6.4	74
25	Dendritic cell immunotherapy for stage IV melanoma. Melanoma Research, 2007, 17, 316-322.	1.2	46
26	Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction. British Journal of Cancer, 2007, 96, 600-608.	6.4	43
27	The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Research, 2006, 8, 402.	5.0	13
28	Dendritic cell immunotherapy for breast cancer. Expert Opinion on Biological Therapy, 2006, 6, 591-604.	3.1	18
29	Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunology and Cell Biology, 2006, 84, 295-302.	2.3	20
30	MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide. European Journal of Immunology, 2005, 35, 681-689.	2.9	14
31	HLA-DR+ Immature Cells Exhibit Reduced Antigen-Presenting Cell Function But Respond to CD40 Stimulation. Neoplasia, 2005, 7, 1123-1132.	5.3	15
32	A Population of HLA-DR+ Immature Cells Accumulates in the Blood Dendritic Cell Compartment of Patients with Different Types of Cancer. Neoplasia, 2005, 7, 1112-1122.	5.3	60
33	Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Research, 2005, 8, R5.	5.0	45
34	Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene, 2004, 23, 4060-4067.	5.9	169
35	Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunology, Immunotherapy, 2003, 52, 387-395.	4.2	175
36	Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 889-896.	2.8	59

#	Article	IF	Citations
37	In vitro anti-tumour activity of Î±-galactosylceramide-stimulated human invariant VÎ±24+NKT cells against melanoma. British Journal of Cancer, 2001, 85, 741-746.	6.4	44
38	Lentiviral Vector-Mediated Tyrosinase-Related Protein 2 Gene Transfer to Dendritic Cells for the Therapy of Melanoma. Human Gene Therapy, 2001, 12, 2203-2213.	2.7	66
39	Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines. European Journal of Immunology, 2000, 30, 671-677.	2.9	22
40	Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: Implications for molecular mimicry in autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2279-2284.	7.1	68
41	Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology, 1999, 31, 116-122.	0.6	20
42	The Labyrinthine Ways of Cancer Immunotherapyâ€“T Cell, Tumor Cell Encounter: â€œHow Do I Lose Thee? Let Me Count the Waysâ€¦ Advances in Cancer Research, 1998, 75, 203-249.	5.0	23
43	A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection.. Journal of Clinical Investigation, 1998, 102, 1551-1558.	8.2	62
44	Dominant Cytotoxic T Lymphocyte Response to the Immediateâ€EarlyTransâ€•Activator Protein, BZLF1, in Persistent Type A or B Epsteinâ€Barr Virus Infection. Journal of Infectious Diseases, 1997, 176, 1068-1072.	4.0	19
45	IMMUNOTHERAPY, INCLUDING GENE THERAPY, FOR METASTATIC MELANOMA. ANZ Journal of Surgery, 1997, 67, 834-841.	0.7	9
46	A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunology, Immunotherapy, 1997, 44, 10-20.	4.2	101
47	Strategies Involved in Developing an Effective Vaccine for EBV-Associated Diseases. Advances in Cancer Research, 1996, 69, 213-245.	5.0	52
48	Recruitment during Infectious Mononucleosis of CD3+CD4+CD8+Virus-Specific Cytotoxic T Cells Which Recognise Epsteinâ€“Barr Virus Lytic Antigen BHRF1. Virology, 1996, 219, 489-492.	2.4	41
49	The ecology and pathology of Epsteinâ€Barr virus. Immunology and Cell Biology, 1995, 73, 489-504.	2.3	21
50	Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus.. Journal of Experimental Medicine, 1994, 180, 2335-2340.	8.5	290
51	Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus. European Journal of Immunology, 1992, 22, 183-189.	2.9	43
52	Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component. Cellular Immunology, 1991, 132, 295-307.	3.0	25
53	Oligopeptide Induction of a Secondary Cytotoxic T-cell Response to Epstein-Barr Virus In Vitro. Scandinavian Journal of Immunology, 1991, 33, 411-420.	2.7	4
54	Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9478-9482.	7.1	33

#	Article	IF	Citations
55	Cytotoxic T lymphocyte discrimination between type A Epstein–Barr virus transformants is mapped to an immunodominant epitope in EBNA 3. Journal of General Virology, 1991, 72, 405-409.	2.9	11
56	Patterns of reactivity of Epstein-Barr virus-specific T cells in A-type donor cultures after reactivation with autologous A- or B-type transformants. Cellular Immunology, 1990, 127, 47-55.	3.0	8
57	Lymphokine-activated killer (lak) cells discriminate between epstein-barr virus (ebv)-positive burkitt's lymphoma cells. International Journal of Cancer, 1990, 46, 399-404.	5.1	7
58	An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).. Journal of Experimental Medicine, 1990, 171, 345-349.	8.5	175
59	Interleukin-2 receptors in infectious mononucleosis. Immunology Letters, 1989, 23, 139-142.	2.5	3
60	T lymphocytes in infectious mononucleosis; Effect of ILâ€2 on the outgrowth of Epsteinâ€Barr virusâ€infected cells. Immunology and Cell Biology, 1989, 67, 49-55.	2.3	0
61	The value of MLA 144 culture fluid for the isolation of human immunodeficiency virus. Immunology and Cell Biology, 1989, 67, 147-149.	2.3	4